Kim, Ju Hwan; Shen, Chin-Yao; Au, Philip Chun-Ming; Baek, Yeon-Hee; Cheung, Ching-Lung; Chung, Wei-Pang; Kleinman, Nora Joelle; ... Lai, Edward Chia-Cheng; + view all Kim, Ju Hwan; Shen, Chin-Yao; Au, Philip Chun-Ming; Baek, Yeon-Hee; Cheung, Ching-Lung; Chung, Wei-Pang; Kleinman, Nora Joelle; Lam, Tai Chung; Liao, Tzu-Chi; Lin, Tzu-Chieh; Shin, Ju-Young; Sing, Chor-Wing; Wong, Ian Chi Kei; Lai, Edward Chia-Cheng; - view fewer (2022) Bone-targeting agents in major solid tumour metastases: a multinational cohort study. BMJ Supportive & Palliative Care 10.1136/bmjspcare-2021-003062. (In press).

Preview

Text Wong_Epi and patterns of BTAs in Asia- 20220125 revised clean.pdf Download (382kB) | Preview

Abstract

OBJECTIVE: To describe the epidemiology, clinical characteristics and utilisation patterns of bone-targeting agents (BTAs) in patients with bone metastases from breast, prostate and lung cancer. METHODS: This is a multinational retrospective cohort study including patients with three major solid tumours (breast, prostate and lung cancer) and newly initiated on BTAs (ie, denosumab, zoledronic acid and pamidronate). Records were retrieved from nationwide health databases from Hong Kong and Taiwan (HK and TW: 2013–2017) and Korea (KR: 2012–2016). Descriptive analyses included the annual incidence rates of bone metastases and the cumulative incidence curves of BTA initiation. We used Sankey diagrams to visualise the dynamic BTA utilisation patterns. RESULTS: The annual incidence rate of bone metastases ranged from 3.5% to 4.5% in TW, from 9.6% to 10.3% in HK and from 2.9% to 3.8% in KR. We identified 14.1% (5127), 9.3% (883) and 9.4% (4800) of patients with bone metastases newly initiated on BTAs in TW, HK and KR, respectively. The most frequently used BTA in TW (67.1%) and HK (51.9%) was denosumab, while in KR (84.8%) it was zoledronic acid. Sankey diagrams indicated the proportion of patients remaining on denosumab was highest in TW and HK, while it was zoledronic acid in KR. Specifically, in TW, patients who were on bisphosphonates or had discontinued treatment frequently switched to or reinitiated denosumab. CONCLUSIONS: We found the rate of BTA utilisation remained low across all sites and tumour types in recent years. The dynamic utilisation patterns of BTAs provide better understanding of the treatment landscape for future evaluation of associated outcomes of patients.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item